拉米夫定联合疗法治疗乙肝早期肝硬化的初步观察

Effects of combination therapy with lamivudine on HBV-related early liver cirrhosis

【目的】观察拉米夫定联合疗法治疗乙肝早期肝硬化的作用。【方法】67例乙肝早期肝硬化患者分为A组(n=32)和B组(n=35),两组治疗前的基线资料无明显差异(P>0.05)。其中,A组给予拉米夫定,100mg/次,1次/d;B组除按上述方法服用拉米夫定外,同时给予舒肝饮丸,9g/次,3次/d;肝氨散,3.5g/次,3次/d,疗程为1年。观察治疗前后乙肝病毒学标志物、肝功能生化的改变。【结果】治疗后A组和B组均有良好的病毒学应答,但两组比较无明显差异(P>0.05)。两组的肝功能生化指标有明显改善,且联合治疗组肝功能的恢复优于单用拉米夫定组,特别是白蛋白水平的提高更为明显(P<0.01)。【结论】拉米夫定联合疗法在改善乙肝早期肝硬化患者的肝功能方面更为有效。

[Objective] To investigate effect of combination therapy with Lamivudine on HBV-related early liver cirrhosis. [Methods] 67 cases with HBV-related early liver cirrhosis were divided into group A（ n = 32） and group El（ n = 35）. There was no difference between 2 groups at baseline data（ P 〉 0.05）. Patients in group A received lamivudine 100mg once daily for one year. Patients in group B received lamivudine 100rag once daily, and Shu Gan Ying Wan, 9 g, and Gan An San, 3.5 g, 3 times daily for one year. Virological response and biochemical response were observed. [Restilts] Similar good virological responses were seen in both groups. Good Biochemical responses were observed in both groups after one year treatment, and the improvement in group B was much better than in group A, particularly for albuminlevel（ P 〈 0.01）. [Conclusions] Combination therapy with lamivudine is more efficacy on HBV-related early cirrhosis, particularly in biochemical improvement.